» Local antibiotic delivery systems are critical in managing periprosthetic and fracture-related infections, providing high local antibiotic concentrations without systemic side effects. Polymethyl methacrylate (PMMA), the first material to be mixed with antibiotics to perform local antibiotic therapy in orthopaedic history, offers reliable antibiotic delivery above the Minimum Inhibitory Concentration (MIC), typically used with heat-stable antibiotics such as vancomycin, tobramycin, and gentamicin. However, excessive antibiotics can weaken the cement, especially in total joint arthroplasty (TJA). When used for bone defects, a second surgery is often required to replace PMMA with bone grafts. » Calcium sulfate (CaSO 4 ) and hydroxyapatite (HA) combinations provide high antibiotic delivery, with CaSO 4 dissolving over time and CaSO 4 /HA offering better bone conversion than CaSO 4 . They are most effective in small, contained defects and can be mixed with relatively heat-unstable antibiotics. » Tricalcium phosphate (Ca 3 [PO 4 ] 2 ) cements are favored for their biocompatibility and biodegradability, enhancing osteoconductivity and allowing for prolonged antibiotic release. Although clinical studies on Ca 3 (PO 4 ) 2 as an antibiotic carrier are limited, vancomycin is commonly used, showing effective bone formation and infection control with a high bone defect cure and healing rate. » Hydrogels are 3D networks of hydrophilic polymers that absorb water and can form physical barriers against bacterial agents. Defensive antibacterial coatings (DAC) can be loaded with antibiotics and have shown lower postsurgery infection rates in arthroplasty. DACs reduce bacterial adhesion and can promote bone healing when combined with osteogenic factors, while being bioabsorbable and compatible with living tissue. » Antibiotic-impregnated bone grafts combine effective local antibiotic delivery with maximum bone healing potential, particularly for those pretreated with induced membranes. Intramedullary harvest offers an unlimited source of bone graft material.
1 February 2021 in International Immunopharmacology
It is believed that preformed antibodies are responsible for blood transfusion reactions and transplant rejections. In order to remove a tumor, the tissue must be rejected. On the basis of transfusion reaction and transplantation immunology, we hypothesized that allogeneic serum can inhibit tumor growth when injected intra-tumor. Initially, an in vitro cytotoxicity test was conducted using the C57BL/6 serum (intact or decomplemented) in combination with the BALB/c-originating CT26 cell line. The CT26 cell line was used to establish a mouse model of colon cancer. When the tumor was palpable, C57BL/6 serum was injected intra-tumor. In addition to tumor size, hypoxia, metastatic capacity, angiogenesis, and metabolic and inflammatory status, we evaluated matrix metalloproteinase-2 (MMP)-2 and 9, vascular endothelial growth factor (VEGF)-A, Cluster of Designation (CD) 31, CD38 and interleukin (IL)-10. An in vitro experiment showed that heat-inactivated C57BL/6 serum had significantly lower cytotoxic effects on BALB/c-derived CT26 cells than intact C57BL/6 serum or BALB/c serum. In vivo experiments revealed that tumor size, HIF-1α, MMP-2, and MMP-9 levels were significantly lower in the experimental group than in the control group.. In contrast, to control animals, allogeneic serum treatment led to marked reductions in CD31, VEGF-1, CD38, and IL-10 levels. A new approach to serum or plasma therapy and allogeneic vaccines for cancer is the intra-tumor injection of allogeneic serum. In light of the ease and availability of allogeneic immunotherapies, allogeneic serum and plasma therapy could potentially be used as an alternative monotherapy or in combination with other therapies.